State Street SPDR S&P Pharmaceuticals ETF
XPH
71 hedge funds and large institutions have $105M invested in State Street SPDR S&P Pharmaceuticals ETF in 2024 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 19 increasing their positions, 22 reducing their positions, and 10 closing their positions.
4.46% more ownership
Funds ownership: 51.92% → 56.38% (+4.5%)
3% less funds holding
Funds holding: 73 → 71 (-2)
9% less capital invested
Capital invested by funds: $115M → $105M (-$9.9M)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
14% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 22
44% less call options, than puts
Call options by funds: $839K | Put options by funds: $1.51M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EH
Equitable Holdings
New York
|
+$10.6M |
| 2 |
Jane Street
New York
|
+$1.97M |
| 3 |
RW
Rockport Wealth
Fairview Park,
Ohio
|
+$1.85M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$343K |
| 5 |
Two Sigma Investments
New York
|
+$292K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$4.69M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$2.67M |
| 3 |
Morgan Stanley
New York
|
-$2.24M |
| 4 |
LPL Financial
San Diego,
California
|
-$2.07M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.37M |
XPH Hedge Fund Activity: Q2 2024 in Review
71 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q2 2024, worth a combined $105M — down 8.6% from $115M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of XPH and 9 opened new positions — a net loss of 1 holder — while 22 trimmed existing stakes and 19 added.
The largest buyer was Equitable Holdings, opening a new position worth an estimated $10.6M. The largest seller was Goldman Sachs, cutting an estimated $4.69M.
- 71 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q2 2024, down from 73 in Q1 2024.
- Funds reported $105M of State Street SPDR S&P Pharmaceuticals ETF stock for Q2 2024, down 8.6% quarter-over-quarter.
- 9 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q2 2024 and 10 closed out, a net change of -1 holder.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q2 2024 was Equitable Holdings, an estimated $10.6M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q2 2024 was Goldman Sachs, an estimated $4.69M sold.
Based on aggregated 13F filings for Q2 2024.